DOCSLIB.ORG

Efficacy of Administering Simultaneous Oral Perchlorate and Intravenous 99 M Tc0 for Brain Scanning

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy of Administering Simultaneous Oral Perchlorate and Intravenous 99 M Tc0 for Brain Scanning Efficacy of Administering Simultaneous Oral Perchlorate and 99 Intravenous m Tc04 - for Brain Scanning Mary E. Maxwell and Bonnie J. Baggenstoss St. Paul-Ramsey Hospital and Medical Center, St. Paul, Minnesota Brain scans were performed using the following TABLE 1. Methods of Perchlorate Administration methods: (A) oral administration of perchlorate at least 30 min before i.v. injection of 99mTc-pertechnetate Number of Group Method studies (99mTc04 -) and (B) simultaneous administration of oral 99 perchlorate and i.v. mTc04 -.The scans were retrospec­ Treat with perchlorate at least 30 min 1,558 tively reviewed for choroid plexus uptake of technetium before i.v. injection of 99mTc04 2 Simultaneous administration of oral 1,233 and scan quality. The simultaneous administration of oral perchlorate a·nd i.v. 99mTc04 99 perchlorate and i.v. mTc04 - is an effective method of 3 No perchlorate given ___!Q performing brain scans and should replace outdated pro­ Total 2,938 tocols requiring treatment with perchlorate before i.v. administration of pertechnetate. The syrup was prepared by (A) dissolving the sodium Most nuclear medicine laboratories use a brain scan perchlorate in distilled water, (B) dissolving the para­ protocol that requires the administration of a per­ hens in ethyl alcohol, and (c) adding the alcohol/ chlorate treating agent, either sodium or potassium, paraben solution to the aqueous sodium perchlorate and 99 before the i.v. administration of mTc04 -. The pre­ bringing the combination to the appropriate volume treatment plan requires an expenditure of extra time with cherry syrup. The final solution should be refrig­ and effort for both technologist and patient. The erated to insure stability and increased palatability. primary purpose of this study was to determine if oral The brain scans were arranged into three groups blocking agents administered simultaneously with i.v. according to the method of perchlorate treatment 99 mTc04 - would effectively block the choroid plexus. (Table 1). The scans were performed on either a recti­ linear scanner or a scintillation camera at 45-120 min 99 Materials and Methods after the injection of mTc04 -. All of the 2,938 scans were subjectively evaluated to Brain scans performed on 2,938 patients at St. Paul­ ascertain the presence or absence of choroid plexus Ramsey Hospital were retrospectively reviewed to 99 activity and overall scan quality. assess mTc04 - uptake in the choroid plexus. A per­ chlorate treatment method was used on 2,791 of these patients. The remaining 147 brain scans were performed Results without any perchlorate treatment because of the Brain scans performed after the. simultaneous 99 patients' inability to ingest oral medications. Twenty­ administration of oral Cl04 and i.v. mTc04 - were com­ 99 three of the patients received mTc-DTPA, which does parable to scans performed using a Cl04 pretreatment 99 not require treatment with perchlorate(/). before administering the i.v. mTc04- (Fig. I). There The choroid plexus blocking agents used were either was no evidence of pertechnetate uptake in the choroid 250-500 mg potassium perchlorate (KC104 ) in capsule plexus on any of the studies reviewed in the perchlorate­ form or 500 mg sodium perchlorate (NaC104 ) in a treated series. cherry syrup solution made in the hospital pharmacy When no oral blocking agent was used (147 scans), and consisting of the following: sodium perchlorate, 50 gm; methyl paraben, 2 gm; propyl paraben, 0.2 gm; ethyl alcohol USP, 8.3 ml; distilled water, 500 ml; and For reprints contact: Mary E. Maxwell, Div. of Nuclear Medicine, cherry syrup added to bring the total solution to 1,000 St. Paul-Ramsey Hospital and Medical Center, St. Paul, Minn. mi. 55101. 138 JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY FIG. 1. Brain scans of same patient demon­ strate comparable overall quality and no evidence of choroid plexus uptake. (A) Simultaneous oral 9 perchlorate and i.v. 9 mTc04 - method and (B) 30- min pretreatment with perchlorate before adminis­ tration of i.v. 99mTc. FIG. 2. Brain scans demonstrate increased area of activity in choroid plexus due to patient"s in­ ability to ingest oral perchlorate. (A) Right lateral. (B) posterior. (C) left lateral. and (D) anterior views. 62% (124) demonstrated increased activity in the region that received oral KCI04 before the intravenous 99 of the choroid plexus (Fig. 2). mTc04 -. Qualitative and quantitative analyses of their work showed that the simultaneous administration method was equally as effective as the perchlorate pre­ Discussion treatment method, and that, if indicated for human use, This study has demonstrated that oral perchlorate the simultaneous method could effectively eliminate the 99 and i.v. mTc04 - can be administered simultaneously pretreatment methods currently used. without compromising scan quality. The ability of the Some observers have found that without perchlorate 99 perchlorate ion to effectively enhance brain scan images blockage, uptake of mTc04 - in the choroid plexus oc­ is well documented but not well understood (2-5). Re­ curred in only l-10% of the population (6). This study sults of this study support the findings of Harper, et a! revealed a 62% incidence of choroid plexus uptake of 99 (2) who did a comparison of concentration ratios of mTc04 - when perchlorate was not administered 99 mTc04 - following i.v. injection in dogs. Their study (Table 2). consisted of a control group that received only Technetium-99m-DTPA may be used as an alternate 99 intravenously injected mTc04 -,a group that received a radiopharmaceutical when the patient cannot ingest 99 mTc04 - fNaCI04 solution intravenously, and a group perchlorate. This radiopharmaceutical combines the VOLUME 3, NUMBER 3 139 waiting period for outpatients was reduced by a factor TABLE 2. Qualitative Data on Patients Receiving of 2. i.v. 99mTc04 without Perchlorate Scan Number of finding studies Acknowledgment Uptake in the choroid plexus region only 33 We wish to thank Robert R. McClelland for his help Pathology identified outside choroid plexus region as well as choroid plexus activity 31 with the preparation of this manuscript. Choroid plexus uptake and/or pathology in the choroid plexus region 13 No choroid plexus or pathologic activity 47 Total 124 References I. Hauser W, Atkins HL, Nelson KG, et al: Technetium-99m DTPA: A new radiopharmaceutical for brain and kidney scanning. physical properties of the radionuclide 9*Tc0,- and the Radio1og.v 94:679-684, 1970 2. Harper AG, Friedman BI, Avis KE, et al: Perchlorate blocking biologic properties of chelating agents, which do not of 99mTc0,- uptake by simultaneous intravenous injection in dogs. J concentrate in any organs (1). The use of 99mTc-DTPA Nucl Med 13:363-366, 1972 in brain scanning eliminates a major source of error in 3. Hirsch JI, Sharpe AR, Garnett W: The role of potassium interpretation in the choroid plexus region on brain perchlorate in 99m technetium brain scanning. Drug Intelligence and scans. Clinical Pharmacy 5:252-257, 197 1 4. Oldendorf WH, Sisson WN, Iisaka Y: Compartmental redis- Experience at this hospital indicated that overall tribution of 99mTc-pertechnetatein the presence of perchlorate ion and laboratory efficiency was improved with the use of the its relation to plasma protein binding. J Nucl Med 11:85-88, 1970 simultaneous method described. The technologist's and 5. Buttfield IH, Wrench JC, Adiseshan N, et al: Intravenous perchlorate in brain scanning: Effects on choroid plexus and lesion the patient's time was utilized more efficiently. The daily visibility. J Nucl Med 14543-545, 1973 schedule of studies was more flexible due to the shorter 6. Maynard CD: Clinical~uclearMedicine. Philadelphia, Lea & total procedure time involved with this method, and the Febiger, 1969, p 163 JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY .
Load more

Recommended publications
  • Novel Application of Quantitative Single-Photon Emission Computed
    Original Article | Nuclear Medicine https://doi.org/10.3348/kjr.2017.18.3.543 pISSN 1229-6929 · eISSN 2005-8330 Korean J Radiol 2017;18(3):543-550 Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves’ Disease Hyun Joo Kim, MD1, 2, Ji-In Bang, MD1, Ji-Young Kim, MD, PhD1, Jae Hoon Moon, MD, PhD3, Young So, MD, PhD4, Won Woo Lee, MD, PhD1, 5 Departments of 1Nuclear Medicine and 3Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea; 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Suwon 16229, Korea; 4Department of Nuclear Medicine, Konkuk University Medical Center, Seoul 05030, Korea; 5Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 08826, Korea Objective: Since Graves’ disease (GD) is resistant to antithyroid drugs (ATDs), an accurate quantitative thyroid function measurement is required for the prediction of early responses to ATD. Quantitative parameters derived from the novel technology, single-photon emission computed tomography/computed tomography (SPECT/CT), were investigated for the prediction of achievement of euthyroidism after methimazole (MMI) treatment in GD. Materials and Methods: A total of 36 GD patients (10 males, 26 females; mean age, 45.3 ± 13.8 years) were enrolled for this study, from April 2015 to January 2016. They underwent quantitative thyroid SPECT/CT 20 minutes post-injection of 99mTc- pertechnetate (5 mCi). Association between the time to biochemical euthyroidism after MMI treatment and %uptake, standardized uptake value (SUV), functional thyroid mass (SUVmean x thyroid volume) from the SPECT/CT, and clinical/ biochemical variables, were investigated.
    [Show full text]
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • Fate of Sodium Pertechnetate-Technetium-99M
    JOURNAL OF NUCLEAR MEDICINE 8:50-59, 1967 Fate of Sodium Pertechnetate-Technetium-99m Dr. Muhammad Abdel Razzak, M.D.,1 Dr. Mahmoud Naguib, Ph.D.,2 and Dr. Mohamed El-Garhy, Ph.D.3 Cairo, Egypt Technetium-99m is a low-energy, short half-life iostope that has been recently introduced into clinical use. It is available as the daughter of °9Mowhich is re covered as a fission product or produced by neutron bombardement of molyb denum-98. The aim of the present work is to study the fate of sodium pertechnetate 9OmTc and to find out any difference in its distribution that might be caused by variation in the method of preparation of the parent nuclide, molybdenum-99. MATERIALS & METHODS The distribution of radioactive sodium pertechnetate milked from 99Mo that was obtained as a fission product (supplied by Isocommerz, D.D.R.) was studied in 36 white mice, weighing between 150 and 250 gm each. Normal isotonic saline was used for elution of the pertechnetate from the radionuclide generator. The experimental animals were divided into four equal groups depending on the route of administration of the radioactive material, whether intraperitoneal, in tramuscular, subcutaneous or oral. Every group was further subdivided into three equal subgroups, in order to study the effect of time on the distribution of the pertechnetate. Thus, the duration between administration of the radio-pharma ceutical and sacrificing the animals was fixed at 30, 60 and 120 minutes for the three subgroups respectively. Then the animals were dissected and the different organs taken out.Radioactivityin an accuratelyweighed specimen from each organ was estimated in a scintillation well detector equipped with one-inch sodium iodide thallium activated crystal.
    [Show full text]
  • Package Insert TECHNETIUM Tc99m GENERATOR for the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceuti
    NDA 17693/S-025 Page 3 Package Insert TECHNETIUM Tc99m GENERATOR For the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceutical For intravenous use only Rx ONLY DESCRIPTION The technetium Tc99m generator is prepared with fission-produced molybdenum Mo99 adsorbed on alumina in a lead-shielded column and provides a means for obtaining sterile pyrogen-free solutions of sodium pertechnetate Tc99m injection in sodium chloride. The eluate should be crystal clear. With a pH of 4.5-7.5, hydrochloric acid and/or sodium hydroxide may have been used for Mo99 solution pH adjustment. Over the life of the generator, each elution will provide a yield of > 80% of the theoretical amount of technetium Tc99m available from the molybdenum Mo99 on the generator column. Each eluate of the generator should not contain more than 0.0056 MBq (0.15 µCi) of molybdenum Mo99 per 37 MBq, (1 mCi) of technetium Tc99m per administered dose at the time of administration, and not more than 10 µg of aluminum per mL of the generator eluate, both of which must be determined by the user before administration. Since the eluate does not contain an antimicrobial agent, it should not be used after twelve hours from the time of generator elution. PHYSICAL CHARACTERISTICS Technetium Tc99m decays by an isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging studies is listed in Table 1. Table 1. Principal Radiation Emission Data1 Radiation Mean %/Disintegration Mean Energy (keV) Gamma-2 89.07 140.5 1Kocher, David C., “Radioactive Decay Data Tables,” DOE/TIC-11026, p.
    [Show full text]
  • Loss of Pertechnetate from the Human Thyroid
    LOSS OF PERTECHNETATE FROM THE HUMAN THYROID J. G. Shimmins Regional Dept. of Clinical Physics and Bioengineering, Western Regional Hospital Board, Glasgow, Scotland R. McG. Harden and W. D. Alexander University Department of Medicine, Western Infirmary, Glasgow, Scotland The pertechnetate ion, like the iodide ion, is Magnascanner V (3,6) were started immediately trapped by the thyroid gland (1 ). Several authors after injection and were continued for 45 mm when have claimed that pertechnetate is not bound in the five scans had normally been completed. The scan thyroid (2) and that the gland behaves as a single speed was 100 cm/sec, and the line spacing was compartment (3) . However, the finding of organic 1 cm. Venous blood samples were taken at 2, 8, 15, binding of 9DmTcin rats (4,5) raises the question 30 and 45 mm. One gram perchlorate was given of whether some such binding may not occur in man. orally as a crushed powder in nine subjects 50 mm In this study we have investigated the binding of after the intravenous administration of pertechne pertechnetate in the human gland by measuring the tate. The same amount was given orally to the re rate of pertechnetate discharge from it after per maining four 3 hr after intravenous administra chlorate administration and have compared this rate tion of pertechnetate. Scans were carried out for an of discharge with the normal loss rate of pertechne additional 45 min after perchlorate administration, tate from the thyroid (3). If pertechnetate is Un and blood samples were taken at 2, 8, 15 and 45 bound, it should be possible to discharge it from min.
    [Show full text]
  • Radionuclide Thyroid Scans
    Radionuclide Thyroid Scans Report 2003 1 Purpose The purpose of this guideline is to assist specialists in Nuclear Medicine and Radionuclide Radiology in recommending, performing, interpreting and reporting radionuclide thyroid scans. This guideline will assist individual departments in the formulation of their own local protocols. Background Thyroid scintigraphy is an effective imaging method for assessing the functionality of thyroid lesions including the uptake function of part or all of the thyroid gland. 99TCm pertechnetate is trapped by thyroid follicular cells. 123I-Iodide is both trapped and organified by thyroid follicular cells. Common Indications 1.1 Assessment of functionality of thyroid nodules. 1.2 Assessment of goitre including hyperthyroid goitre. 1.3 Assessment of uptake function prior to radio-iodine treatment 1.4 Assessment of ectopic thyroid tissue. 1.5 Assessment of suspected thyroiditis 1.6 Assessment of neonatal hypothyroidism Procedure 1 Patient preparation 1.1 Information on patient medication should be obtained prior to undertaking study. Patients on Thyroxine (Levothyroxine Sodium) should stop treatment for four weeks prior to imaging, patients on Tri-iodothyronine (T3) should stop treatment for two weeks if adequate images are to be obtained. 1.2 All relevant clinical history should be obtained on attendance, including thyroid medication, investigations with contrast media, other relevant medication including Amiodarone, Lithium, kelp, previous surgery and diet. 1.3 All other relevant investigations should be available including results of thyroid function tests and ultrasound examinations. 1.4 Studies should be scheduled to avoid iodine-containing contrast media prior to thyroid imaging. 2 1.5 Carbimazole and Propylthiouracil are not contraindicated in patients undergoing 99Tcm pertechnetate thyroid scans and need not be discontinued prior to imaging.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ultra-TechneKow FM 2.15-43.00 GBq radionuclide generator 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium pertechnetate (99mTc) injection is produced by means of a (99Mo/99mTc) generator. Technetium (99mTc) decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.01 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. The radionuclide generator containing the parent isotope 99Mo, adsorbed on a chromatographic column delivers sodium pertechnetate (99mTc) injection in sterile solution. The 99Mo on the column is in equilibrium with the formed daughter isotope 99mTc. The generators are supplied with the following 99Mo activity amounts at activity reference time which deliver the following technetium (99mTc) amounts, assuming a 100% theoretical elution yield and 24 hours time from previous elution and taking into account that branching ratio of 99Mo is about 87%: 99mTc activity (maximum theoretical elutable 1.90 3.81 5.71 7.62 9.53 11.43 15.24 19.05 22.86 26.67 30.48 38.10 GBq activity at ART, 06.00 h CET) 99Mo activity (at ART, 06.00 h 2.15 4.30 6.45 8.60 10.75 12.90 17.20 21.50 25.80 30.10 34.40 43.00 GBq CET) The technetium (99mTc) amounts available by a single elution depend on the real yields of the kind of generator used itself declared by manufacturer and approved by National Competent Authority.
    [Show full text]
  • Technetium-99M Pertechnetate Uptake and Scanning in the Evaluation of Thyroid Function 4,(’).,..1.(J
    .—._.-——. ..—-—- ---,- -- -“ ~ .- ,-- c~ ..o~-~ ~ The Medical Research Center (5 :>NJL I&w 7 Brookhaven National J.aboratory IS-5 2!U Upton, L.L, New York =112 ) Technetium-99m Pertechnetate Uptake and Scanning in the Evaluation of Thyroid Function 4,(’).,..1.(j. .“yl~... By HAROLDL. ATXINS -J i Technetium-99m as pertechnetate is ac- radioiodine uptakes, the pertechnetate cumulated by the thyroid but not appre- uptake was sfightly superi&, with only t ciably organified. In this study, a method 5.9% errors in 488 patients. Radioiodine of detem]ining thyroidal uptake from the uptakes were in error in 7.8% of 270 scintiscan is described. The mean uptake individuals. In hyperthyroid patients, the in euthyroid individuals as measured by accuracy of the pertech-netate-uptake was this method was 1.73 * 0.85% with a 89.6% while the radioiodine uptake had normal range of 0.50-4.00$%0. Uptake an accuracy of 75.0%0. Both uptake was not affected by organic blocking determinations were highly inaccurate in agents. In a comparison of the overall hypothyroidism. - “ accuracy of pertechnetate and 24-hr HE UTILIZATION of 1811 for diagnostic thyroid studies has been routine Tfor more than two decades. Despite this, it is not a completely satisfactory agent for this purpose for a number of reasons. A relatively high radiation dose from the energetic beta emission is cause for concern in the light of the experience with the Marshallese exposed to fallout radiation, primarily radio- iodines.1 While no deleterious effects from diagnostic uses of iodine-131 have been demonstrated, they have not been specifically looked for.
    [Show full text]
  • Thyrotoxicosis Due to Atypical Subacute Thyroiditis Scintigraphicaly Presented As Toxic Adenoma – Case Report
    Case Report Annals of Clinical Case Reports Published: 17 Nov, 2016 Thyrotoxicosis due to Atypical Subacute Thyroiditis Scintigraphicaly Presented as Toxic Adenoma – Case Report Željka Aleksić1*, Aleksandar Aleksić2 and Nenad Ristović3 1Department of Nuclear Medicine, Health Center Zaječar, Serbia 2Department of Internal Medicine, Health Center Zaječar, Serbia 3Department of Infectious Disease, Health Center Zaječar, Serbia Abstract Subacute thyroiditis (SAT), also known as DeQuervain's or granulomatous thyroiditis is an inflammatory condition of the thyroid gland, which is usually fully affected. Severe pain and tenderness in the thyroid bed occur typically and are followed by weakness, fatigue, pain in muscles and joints, and light to moderate fever and symptoms of thyrotoxicosis - nervousness, sweating and rapid heart beat and trembling. Temporary elevated serum thyroxin, suppressed TSH and elevated serum markers of inflammation in the acute phase are pathognomonic for the SAT, with diffusely absent binding of radioactive iodine or technetium-pertechnetate in the thyroid gland due to thyrocytes destruction. Rare cases of atypical SAT - painless or with minimal pain, SAT limited to one thyroid lobe or focal thyroiditis, are reported in literature. We report a rare case of a minimally painful SAT associated with functional adenoma in the right lobe of the thyroid gland, which was, in thyrotoxic, acute phase, scintigraphicaly presented as toxic adenoma, in fact representing a functional adenoma tissue unaffected by destructive thyroiditis. Keywords: Atypical subacute thyroiditis; Autonomously functioning thyroid nodule; Toxic adenoma Introduction OPEN ACCESS Subacute thyroiditis (SAT), also known as DeQuervain's or granulomatous thyroiditis is an inflammatory condition of the thyroid gland, which is usually affected as a whole.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Potassium Perchlorate Hazard Summary
    Common Name: POTASSIUM PERCHLORATE CAS Number: 7778-74-7 RTK Substance number: 1577 DOT Number: UN 1489 Date: July 1988 Revision: May 2002 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS * Potassium Perchlorate can affect you when breathed in. No occupational exposure limits have been established for * Contact can irritate the skin and eyes. Potassium Perchlorate. This does not mean that this * Breathing Potassium Perchlorate can irritate the nose and substance is not harmful. Safe work practices should always throat. be followed. * High and repeated exposure may affect the thyroid, white blood cells and kidneys. WAYS OF REDUCING EXPOSURE * Where possible, enclose operations and use local exhaust IDENTIFICATION ventilation at the site of chemical release. If local exhaust Potassium Perchlorate is a colorless to white crystalline ventilation or enclosure is not used, respirators should be (sand-like) solid. It is used in explosives, flares, rocket worn. propellants, photography, as a medication, and as an agent in * Wear protective work clothing. automobile safety air bags. * Wash thoroughly immediately after exposure to Potassium Perchlorate and at the end of the workshift. REASON FOR CITATION * Post hazard and warning information in the work area. In * Potassium Perchlorate is on the Hazardous Substance addition, as part of an ongoing education and training List because it is cited by DOT. effort, communicate all information on the health and * Definitions are provided on page 5. safety hazards of Potassium Perchlorate to potentially exposed workers. HOW TO DETERMINE IF YOU ARE BEING EXPOSED The New Jersey Right to Know Act requires most employers to label chemicals in the workplace and requires public employers to provide their employees with information and training concerning chemical hazards and controls.
    [Show full text]
  • The Outcome of a Calculated Radioiodine Dose Based On
    Malaysian Journal of Medicine and Health Sciences (eISSN 2636-9346) ORIGINAL ARTICLE The Outcome Of A Calculated Radioiodine Dose Based On Pertechnetate Thyroid Uptake Ratio In Treatment For Hyperthyroidism Lee Yeong Fong1,2, Ibrahim Lutfi Shuaib2, Fadzilah Hamzah1 1 Nuclear Medicine Department, Hospital Pulau Pinang, 10990 George Town, Pulau Pinang, Malaysia 2 Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia ABSTRACT Introduction: There are two dosing methods for radioiodine dose administration including empirical fixed dose and calculated dose. Recent meta-analysis supported that dose calculation is better than empirical fixed dose. However, dose calculation by dosimetry or 24 hours radioiodine uptake ratio can be tedious. Pertechnetate thyroid scintig- raphy is a simple nuclear imaging that can be completed on the same day and pertechnetate thyroid uptake ratio determined from the scintigraphy can be used to calculate the radioiodine dose. This research is done to measure the efficacy of the calculated dose regime. Methods: Hyperthyroidism patients referred for first radioiodine therapy were recruited. Pertechnetate thyroid scintigraphy was done and pertechnetate uptake ratio used for dose calculation. The outcome of the treatment was determined at six months. Results: A total of 95 patients were recruited. Six months after treatment, 82.1% of the calculated dose cohort achieved euthyroid or hypothyroid state. Participants with mul- tinodular goitre had higher failure rate than those with Graves’ disease (p=0.032) although there was no difference in the median RAI dose given (p=0.866). Conclusion: This calculated dose method showed good outcome with 82.1% cure rate at six months post treatment.
    [Show full text]